Klinische studies weke delen sarcomen

Op deze pagina

Planned

BI 1403-0032 - Brigimadlin safety roll-over trial 

A Phase II, single arm, open-label, long-term safety rollover trial of oral brigimadlin in patients with solid tumours

Brightline-4 - BI1403-0019

A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 treatment in patients with advanced treatment-naïve or pre-treated dedifferentiated liposarcoma

Ongoing

SaLuDo - PM1183-C-010-22 

Randomized, Controlled, Open-label, Phase IIb /III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma

Closed

I5B-MC-JGDQ

An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments

ANITA EORTC 1506

A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease

ANNOUNCE I5B-MC-JGDJ

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma

DeFi NIR301DT 

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors (DTs)/ Aggressive Fibromatosis (AF)

EPIZYME EZH-202

A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma

MANTRA - RAIN-3201

A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients
with Dedifferentiated Liposarcoma

TRUST EZH-501

Tazemetostat Rollover Study : An Open-Label Rollover Study

Laatste aanpassing: 31 October 2024